GeneTether Therapeutics (XCNQ:GTTX) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. GeneTether Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$0.00 Mil. GeneTether Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was C$1.93 Mil. Therefore, GeneTether Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

GeneTether Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for GeneTether Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Gross-Profit-to-Asset % Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of GeneTether Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, GeneTether Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneTether Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's Gross-Profit-to-Asset % falls into.

GeneTether Therapeutics Gross-Profit-to-Asset % Calculation

GeneTether Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (2.641	+	1.893)	/ 2 )
	=	0	/	2.267
	=	0.00 %

GeneTether Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (1.966	+	1.893)	/ 2 )
	=	0	/	1.9295
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

GeneTether Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines